Concepts (282)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy Complications, Infectious | 23 | 2021 | 103 | 5.080 |
Why?
|
| HIV Infections | 43 | 2023 | 2303 | 2.980 |
Why?
|
| Infectious Disease Transmission, Vertical | 12 | 2021 | 72 | 1.810 |
Why?
|
| Anti-HIV Agents | 15 | 2020 | 420 | 1.470 |
Why?
|
| Microcephaly | 3 | 2018 | 19 | 1.430 |
Why?
|
| Congenital Abnormalities | 2 | 2019 | 21 | 1.340 |
Why?
|
| Pregnancy | 29 | 2023 | 1549 | 1.200 |
Why?
|
| Puerto Rico | 18 | 2024 | 1378 | 1.180 |
Why?
|
| HIV-1 | 16 | 2019 | 706 | 0.980 |
Why?
|
| Pregnancy Outcome | 6 | 2019 | 87 | 0.940 |
Why?
|
| Vaccines | 1 | 2024 | 55 | 0.880 |
Why?
|
| Ritonavir | 6 | 2020 | 14 | 0.840 |
Why?
|
| Cyclonic Storms | 3 | 2021 | 64 | 0.780 |
Why?
|
| Female | 54 | 2023 | 20969 | 0.760 |
Why?
|
| Syphilis | 1 | 2021 | 23 | 0.760 |
Why?
|
| Infant, Newborn | 13 | 2019 | 894 | 0.710 |
Why?
|
| Pregnancy Complications | 2 | 2019 | 126 | 0.670 |
Why?
|
| Adaptation, Psychological | 3 | 2021 | 385 | 0.670 |
Why?
|
| Humans | 58 | 2024 | 37093 | 0.650 |
Why?
|
| AIDS Vaccines | 5 | 2013 | 30 | 0.640 |
Why?
|
| Hospitals, University | 1 | 2017 | 38 | 0.610 |
Why?
|
| Brain | 3 | 2018 | 1346 | 0.560 |
Why?
|
| Adult | 34 | 2021 | 11712 | 0.560 |
Why?
|
| Disasters | 1 | 2017 | 65 | 0.560 |
Why?
|
| Social Support | 2 | 2017 | 394 | 0.560 |
Why?
|
| Health Policy | 2 | 2021 | 165 | 0.550 |
Why?
|
| Reverse Transcriptase Inhibitors | 3 | 2017 | 57 | 0.530 |
Why?
|
| Family | 1 | 2015 | 173 | 0.480 |
Why?
|
| Prospective Studies | 10 | 2024 | 1378 | 0.480 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2015 | 19 | 0.480 |
Why?
|
| Health Personnel | 1 | 2016 | 228 | 0.470 |
Why?
|
| Influenza Vaccines | 2 | 2015 | 55 | 0.450 |
Why?
|
| Benzoxazines | 3 | 2020 | 46 | 0.450 |
Why?
|
| Caregivers | 1 | 2015 | 182 | 0.450 |
Why?
|
| Public Health | 2 | 2018 | 372 | 0.440 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 336 | 0.440 |
Why?
|
| Prejudice | 2 | 2010 | 110 | 0.430 |
Why?
|
| Primary Prevention | 1 | 2012 | 59 | 0.410 |
Why?
|
| Quality of Life | 1 | 2015 | 481 | 0.390 |
Why?
|
| Young Adult | 13 | 2019 | 4268 | 0.380 |
Why?
|
| RNA, Viral | 10 | 2019 | 301 | 0.370 |
Why?
|
| Saquinavir | 2 | 2007 | 3 | 0.360 |
Why?
|
| HIV Protease Inhibitors | 2 | 2015 | 23 | 0.350 |
Why?
|
| T-Lymphocytes | 2 | 2015 | 357 | 0.350 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 864 | 0.350 |
Why?
|
| Emotions | 1 | 2012 | 220 | 0.350 |
Why?
|
| Adolescent | 14 | 2019 | 5363 | 0.350 |
Why?
|
| Viral Load | 10 | 2019 | 312 | 0.340 |
Why?
|
| Education, Public Health Professional | 1 | 2009 | 19 | 0.340 |
Why?
|
| Male | 21 | 2019 | 20025 | 0.330 |
Why?
|
| HIV Fusion Inhibitors | 2 | 2008 | 4 | 0.330 |
Why?
|
| Cyclohexanes | 2 | 2008 | 30 | 0.330 |
Why?
|
| HIV Seropositivity | 3 | 2010 | 190 | 0.320 |
Why?
|
| Health Services Research | 1 | 2009 | 148 | 0.310 |
Why?
|
| Triazoles | 2 | 2008 | 86 | 0.310 |
Why?
|
| Mentors | 1 | 2009 | 127 | 0.310 |
Why?
|
| Research Personnel | 1 | 2009 | 155 | 0.300 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2007 | 2 | 0.300 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2007 | 39 | 0.280 |
Why?
|
| Neoplasms | 1 | 2016 | 1103 | 0.280 |
Why?
|
| Pregnancy Trimester, Second | 3 | 2019 | 16 | 0.270 |
Why?
|
| Lymphocyte Subsets | 1 | 2015 | 21 | 0.260 |
Why?
|
| Infant | 5 | 2019 | 1046 | 0.250 |
Why?
|
| Cohort Studies | 8 | 2019 | 1492 | 0.250 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 2011 | 215 | 0.250 |
Why?
|
| Education | 1 | 2005 | 55 | 0.250 |
Why?
|
| Influenza, Human | 1 | 2015 | 83 | 0.240 |
Why?
|
| Minority Groups | 1 | 2009 | 596 | 0.230 |
Why?
|
| Survivors | 1 | 2005 | 136 | 0.230 |
Why?
|
| Dogs | 1 | 2024 | 149 | 0.230 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2007 | 277 | 0.220 |
Why?
|
| Desogestrel | 2 | 2020 | 4 | 0.220 |
Why?
|
| Immune Tolerance | 1 | 2013 | 65 | 0.220 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2013 | 59 | 0.210 |
Why?
|
| Health Status Disparities | 1 | 2009 | 642 | 0.210 |
Why?
|
| HIV Antigens | 2 | 2008 | 5 | 0.210 |
Why?
|
| CD4 Lymphocyte Count | 7 | 2010 | 189 | 0.210 |
Why?
|
| Vaccination | 1 | 2024 | 288 | 0.200 |
Why?
|
| Antibodies, Viral | 2 | 2019 | 262 | 0.190 |
Why?
|
| Middle Aged | 15 | 2020 | 10129 | 0.190 |
Why?
|
| Contraceptive Agents, Female | 1 | 2020 | 23 | 0.180 |
Why?
|
| Lynestrenol | 1 | 2019 | 1 | 0.180 |
Why?
|
| Nicaragua | 1 | 2019 | 3 | 0.180 |
Why?
|
| Guatemala | 1 | 2019 | 17 | 0.180 |
Why?
|
| Contraceptive Agents | 1 | 2019 | 13 | 0.170 |
Why?
|
| Colombia | 1 | 2019 | 20 | 0.170 |
Why?
|
| Peru | 1 | 2019 | 30 | 0.170 |
Why?
|
| Cross-Sectional Studies | 4 | 2019 | 2721 | 0.170 |
Why?
|
| Pregnancy Trimester, First | 1 | 2019 | 17 | 0.170 |
Why?
|
| Brazil | 1 | 2019 | 64 | 0.170 |
Why?
|
| Language Development | 1 | 2019 | 24 | 0.170 |
Why?
|
| Premature Birth | 2 | 2019 | 75 | 0.170 |
Why?
|
| Drug Therapy, Combination | 4 | 2010 | 227 | 0.170 |
Why?
|
| Immunoglobulin M | 1 | 2019 | 82 | 0.170 |
Why?
|
| Eye Abnormalities | 1 | 2018 | 6 | 0.170 |
Why?
|
| Fetal Growth Retardation | 1 | 2019 | 50 | 0.170 |
Why?
|
| Child | 2 | 2024 | 3131 | 0.160 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2018 | 42 | 0.160 |
Why?
|
| Attitude to Health | 3 | 2013 | 325 | 0.160 |
Why?
|
| Child Development | 1 | 2019 | 88 | 0.160 |
Why?
|
| Pre-Eclampsia | 1 | 2019 | 61 | 0.160 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2023 | 33 | 0.160 |
Why?
|
| Gels | 4 | 2019 | 42 | 0.160 |
Why?
|
| Relief Work | 1 | 2017 | 7 | 0.150 |
Why?
|
| Qualitative Research | 2 | 2021 | 446 | 0.150 |
Why?
|
| Antiviral Agents | 2 | 2017 | 157 | 0.150 |
Why?
|
| Databases, Factual | 1 | 2018 | 291 | 0.150 |
Why?
|
| Calcinosis | 1 | 2017 | 59 | 0.150 |
Why?
|
| HIV | 3 | 2007 | 98 | 0.150 |
Why?
|
| Obstetrics | 1 | 2017 | 37 | 0.150 |
Why?
|
| Rectum | 1 | 2017 | 22 | 0.150 |
Why?
|
| Pyridazines | 1 | 2016 | 14 | 0.140 |
Why?
|
| Treatment Outcome | 5 | 2017 | 1369 | 0.140 |
Why?
|
| Double-Blind Method | 4 | 2011 | 286 | 0.140 |
Why?
|
| Love | 1 | 2015 | 6 | 0.140 |
Why?
|
| Anti-Retroviral Agents | 3 | 2015 | 147 | 0.140 |
Why?
|
| Sexual Behavior | 6 | 2017 | 609 | 0.130 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2006 | 41 | 0.130 |
Why?
|
| Nitriles | 2 | 2016 | 69 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 481 | 0.130 |
Why?
|
| Pyrimidines | 2 | 2016 | 118 | 0.130 |
Why?
|
| Social Justice | 2 | 2018 | 55 | 0.120 |
Why?
|
| Administration, Rectal | 3 | 2019 | 18 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 204 | 0.120 |
Why?
|
| Retrospective Studies | 2 | 2018 | 2026 | 0.120 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2017 | 221 | 0.120 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 2 | 0.120 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 1502 | 0.110 |
Why?
|
| Cyclopropanes | 3 | 2020 | 40 | 0.110 |
Why?
|
| Alkynes | 3 | 2020 | 50 | 0.110 |
Why?
|
| Culture | 2 | 2013 | 173 | 0.110 |
Why?
|
| Patient Compliance | 2 | 2005 | 212 | 0.110 |
Why?
|
| Occupational Diseases | 1 | 2013 | 47 | 0.110 |
Why?
|
| Oligopeptides | 1 | 2013 | 102 | 0.110 |
Why?
|
| Flow Cytometry | 2 | 2015 | 399 | 0.110 |
Why?
|
| Pyridines | 1 | 2013 | 116 | 0.110 |
Why?
|
| Caribbean Region | 1 | 2012 | 69 | 0.110 |
Why?
|
| Patient Selection | 1 | 2013 | 164 | 0.100 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2016 | 11 | 0.100 |
Why?
|
| Down Syndrome | 1 | 2011 | 29 | 0.100 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 1067 | 0.100 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2011 | 33 | 0.100 |
Why?
|
| Area Under Curve | 3 | 2015 | 88 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2012 | 441 | 0.100 |
Why?
|
| Delivery, Obstetric | 3 | 2006 | 40 | 0.090 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 49 | 0.090 |
Why?
|
| Perinatal Care | 2 | 2008 | 15 | 0.090 |
Why?
|
| United States | 4 | 2009 | 4223 | 0.090 |
Why?
|
| Contraceptive Devices, Female | 2 | 2020 | 2 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2010 | 80 | 0.090 |
Why?
|
| Risk Factors | 6 | 2012 | 3562 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2015 | 583 | 0.090 |
Why?
|
| Drug Interactions | 2 | 2020 | 141 | 0.090 |
Why?
|
| Genotype | 3 | 2020 | 730 | 0.080 |
Why?
|
| Models, Educational | 1 | 2009 | 44 | 0.080 |
Why?
|
| Psychometrics | 1 | 2010 | 318 | 0.080 |
Why?
|
| Immunity, Cellular | 2 | 2008 | 70 | 0.080 |
Why?
|
| Herpes Genitalis | 1 | 2008 | 6 | 0.080 |
Why?
|
| Herpesvirus 2, Human | 1 | 2008 | 9 | 0.080 |
Why?
|
| Homosexuality, Male | 3 | 2019 | 458 | 0.080 |
Why?
|
| Drug Administration Schedule | 3 | 2016 | 143 | 0.080 |
Why?
|
| Lamivudine | 1 | 2007 | 20 | 0.080 |
Why?
|
| Drug Resistance, Viral | 3 | 2010 | 63 | 0.080 |
Why?
|
| Postpartum Period | 2 | 2015 | 66 | 0.080 |
Why?
|
| Cultural Competency | 1 | 2009 | 131 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2012 | 400 | 0.080 |
Why?
|
| Animals | 1 | 2024 | 15081 | 0.070 |
Why?
|
| Cooperative Behavior | 1 | 2009 | 219 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2017 | 224 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2007 | 201 | 0.070 |
Why?
|
| Prenatal Care | 1 | 2007 | 73 | 0.070 |
Why?
|
| Puerperal Disorders | 1 | 2006 | 6 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2007 | 339 | 0.070 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2008 | 164 | 0.070 |
Why?
|
| Schools, Medical | 1 | 2007 | 198 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 494 | 0.070 |
Why?
|
| Papillomaviridae | 1 | 2006 | 127 | 0.070 |
Why?
|
| Protease Inhibitors | 1 | 2005 | 49 | 0.070 |
Why?
|
| Medication Adherence | 2 | 2017 | 179 | 0.060 |
Why?
|
| Mothers | 1 | 2007 | 181 | 0.060 |
Why?
|
| Cognition Disorders | 1 | 2006 | 233 | 0.060 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 185 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2015 | 250 | 0.060 |
Why?
|
| Fetal Weight | 1 | 2023 | 9 | 0.060 |
Why?
|
| Vagina | 2 | 2020 | 81 | 0.060 |
Why?
|
| Fetal Development | 1 | 2023 | 29 | 0.060 |
Why?
|
| Women's Health | 1 | 2004 | 145 | 0.060 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2013 | 8 | 0.060 |
Why?
|
| Zidovudine | 1 | 2003 | 34 | 0.060 |
Why?
|
| Immunophenotyping | 1 | 2013 | 57 | 0.060 |
Why?
|
| Genitalia, Female | 1 | 2003 | 26 | 0.050 |
Why?
|
| Mass Screening | 1 | 2007 | 462 | 0.050 |
Why?
|
| Adenoviridae Infections | 1 | 2012 | 4 | 0.050 |
Why?
|
| Circumcision, Male | 1 | 2012 | 8 | 0.050 |
Why?
|
| Sexual Partners | 2 | 2017 | 314 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2012 | 62 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2012 | 72 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2006 | 336 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2012 | 158 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2005 | 484 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2008 | 534 | 0.050 |
Why?
|
| Time Factors | 2 | 2012 | 1742 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2021 | 48 | 0.050 |
Why?
|
| Ethinyl Estradiol | 1 | 2020 | 9 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2020 | 49 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 114 | 0.040 |
Why?
|
| Progesterone | 1 | 2019 | 113 | 0.040 |
Why?
|
| Reproductive Rights | 1 | 2018 | 2 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2020 | 191 | 0.040 |
Why?
|
| DNA, Viral | 3 | 2006 | 304 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 41 | 0.040 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2008 | 7 | 0.040 |
Why?
|
| Transaminases | 1 | 2008 | 8 | 0.040 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2005 | 389 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2008 | 64 | 0.040 |
Why?
|
| Hepatitis B | 1 | 2008 | 38 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 276 | 0.040 |
Why?
|
| Receptors, CCR5 | 1 | 2008 | 61 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2013 | 1418 | 0.040 |
Why?
|
| Survival Analysis | 3 | 2004 | 325 | 0.040 |
Why?
|
| Lubricants | 1 | 2017 | 4 | 0.040 |
Why?
|
| Disease Progression | 3 | 2006 | 601 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2018 | 138 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2018 | 155 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 268 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2008 | 125 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 108 | 0.040 |
Why?
|
| Glycerol | 1 | 2017 | 28 | 0.040 |
Why?
|
| Aged | 2 | 2008 | 6741 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2008 | 308 | 0.030 |
Why?
|
| Mutation | 2 | 2011 | 1095 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 767 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2006 | 455 | 0.030 |
Why?
|
| Infant, Premature | 2 | 2005 | 129 | 0.030 |
Why?
|
| Dominican Republic | 1 | 2013 | 20 | 0.030 |
Why?
|
| HIV Seroprevalence | 1 | 2013 | 14 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 404 | 0.030 |
Why?
|
| Bilirubin | 1 | 2013 | 17 | 0.030 |
Why?
|
| Informed Consent | 1 | 2013 | 31 | 0.030 |
Why?
|
| Plasma | 1 | 2013 | 31 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2013 | 25 | 0.030 |
Why?
|
| Haiti | 1 | 2013 | 68 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2005 | 583 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 267 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2008 | 885 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2008 | 1130 | 0.030 |
Why?
|
| Pregnancy Trimesters | 1 | 2011 | 14 | 0.030 |
Why?
|
| Prevalence | 2 | 2006 | 1455 | 0.030 |
Why?
|
| Nucleotides | 1 | 2011 | 36 | 0.020 |
Why?
|
| Adenine | 1 | 2011 | 44 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2011 | 22 | 0.020 |
Why?
|
| Nucleosides | 1 | 2011 | 30 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2013 | 451 | 0.020 |
Why?
|
| Smoking | 2 | 2006 | 940 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2007 | 25 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2007 | 30 | 0.020 |
Why?
|
| Creatinine | 1 | 2007 | 103 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 898 | 0.020 |
Why?
|
| Wechsler Scales | 1 | 2006 | 6 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 127 | 0.020 |
Why?
|
| Triplets | 1 | 2005 | 4 | 0.020 |
Why?
|
| Twins | 1 | 2005 | 17 | 0.020 |
Why?
|
| Comorbidity | 1 | 2008 | 623 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2005 | 55 | 0.020 |
Why?
|
| Memory | 1 | 2006 | 170 | 0.020 |
Why?
|
| Parturition | 1 | 2005 | 24 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2008 | 753 | 0.020 |
Why?
|
| Self Disclosure | 1 | 2005 | 42 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2004 | 149 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2004 | 38 | 0.020 |
Why?
|
| Gestational Age | 1 | 2005 | 190 | 0.020 |
Why?
|
| Half-Life | 1 | 2004 | 54 | 0.010 |
Why?
|
| Labor, Obstetric | 1 | 2004 | 16 | 0.010 |
Why?
|
| Gravidity | 1 | 2003 | 3 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2004 | 98 | 0.010 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2004 | 121 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 550 | 0.010 |
Why?
|
| Virus Shedding | 1 | 2003 | 8 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 2003 | 42 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 1033 | 0.010 |
Why?
|
| Incidence | 1 | 2004 | 922 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2003 | 974 | 0.010 |
Why?
|